In early March 2020, Pfizer’s chief scientific officer was summoned to the White House to discuss the disease that was sweeping across the world.
Mikael Dolsten did not talk about the vaccine that would later bring the company fame and enormous wealth: instead, in those early days, he described how the drugmaker was working on a way to treat patients who had developed Covid-19.
“We have identified compounds — medicines — that we think . . . have good, high probability to be active against Covid-19,” he told President Donald Trump.
您已阅读5%（536字），剩余95%（10435字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。